STAT+: The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma
Share- Nishadil
- January 08, 2024
- 0 Comments
- 0.22 minutes read
- 51 Views
ohnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — . The deal, disclosed as the biopharma field marked , extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry. Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.
Disclaimer: This article was generated in part using artificial intelligence and may contain errors or omissions. The content is provided for informational purposes only and does not constitute professional advice. We makes no representations or warranties regarding its accuracy, completeness, or reliability. Readers are advised to verify the information independently before relying on
